Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 OXYQUINOLINE versus MPI INDIUM DTPA IN 111.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 OXYQUINOLINE versus MPI INDIUM DTPA IN 111.
INDIUM IN 111 OXYQUINOLINE vs MPI INDIUM DTPA IN 111
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In 111 oxyquinoline is a radiolabeled compound that chelates indium-111 with oxyquinoline. The lipophilic complex penetrates cell membranes and binds to intracellular components, primarily in leukocytes (neutrophils). After intravenous injection, the radiolabeled cells accumulate at sites of inflammation or infection, allowing gamma camera imaging to detect focal areas of abnormal leukocyte localization.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
1-2 mCi (37-74 MBq) labeled autologous leukocytes, administered intravenously over 1-2 minutes.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours for the free indium ion, but biological half-life for labeled cells can be 1-2 days depending on cell type.
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Renal excretion approximately 70-80% within 24 hours; fecal excretion less than 5%.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical